Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome

J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e715-e717. doi: 10.1111/jdv.18868. Epub 2023 Jan 21.

Ingrid Lazaridou¹, Julien Calvani^{2

3

4}, Elissa Annabi¹, Hélène Moins-Teisserenc^{4

5

6}, Van Anh Ta⁶, Jacqueline Rivet², Caroline Ram-Wolff¹, Maëlle Dumont¹, Thibault Mahevas¹, Marie-Dominique Vignon-Pennamen², Samia Mourah^{3

4

7}, Jean-David Bouaziz^{1

3

4}, Baptiste Louveau^{3

4

7}, Martine Bagot^{1

3

4}, Maxime Battistella^{2

3

4}, Adèle de Masson^{1

3

4}

¹ Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.
² Department of Pathology, APHP, Saint-Louis Hospital, Paris, France.
³ INSERM U976, Institut de Recherche Saint-Louis, Paris, France.
⁴ Université Paris Cité, Paris, France.
⁵ Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France.
⁶ INSERM U1160, Institut de Recherche Saint-Louis, Paris, France.
⁷ Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France.

No abstract available

Publication types